Public Employees Retirement Association of Colorado Lowers Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Public Employees Retirement Association of Colorado lessened its position in Hologic, Inc. (NASDAQ:HOLX) by 0.4% in the 4th quarter, Holdings Channel reports. The fund owned 272,215 shares of the medical equipment provider’s stock after selling 1,193 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Hologic were worth $19,624,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Benson Investment Management Company Inc. purchased a new position in Hologic in the 4th quarter valued at approximately $4,832,000. Principal Financial Group Inc. increased its stake in shares of Hologic by 0.6% during the 4th quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock valued at $19,547,000 after acquiring an additional 1,606 shares during the last quarter. Clean Yield Group raised its stake in Hologic by 18.9% during the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock worth $3,291,000 after purchasing an additional 7,266 shares during the period. JPMorgan Chase & Co. increased its stake in Hologic by 21.3% during the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock worth $110,700,000 after acquiring an additional 238,222 shares during the last quarter. Finally, Nordea Investment Management AB increased its position in shares of Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after acquiring an additional 544,889 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Price Performance

Shares of HOLX opened at $58.02 on Monday. The firm’s 50 day moving average price is $61.02 and its 200 day moving average price is $69.93. Hologic, Inc. has a twelve month low of $55.89 and a twelve month high of $84.67. The firm has a market cap of $13.02 billion, a PE ratio of 18.30, a PEG ratio of 2.14 and a beta of 0.82. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Royal Bank of Canada dropped their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 6th. Stephens reiterated an “overweight” rating and issued a $84.00 price target on shares of Hologic in a research note on Thursday, February 6th. Leerink Partners downgraded Hologic from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Citigroup decreased their price objective on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Finally, Raymond James reaffirmed an “outperform” rating and set a $90.00 target price (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Hologic presently has a consensus rating of “Hold” and a consensus price target of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.